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Many current chemotherapies function by damaging genomic DNA in rapidly dividing cells
ultimately leading to cell death.This therapeutic approach differentially targets cancer cells
that generally display rapid cell division compared to normal tissue cells. However, although
these treatments are initially effective in arresting tumor growth and reducing tumor bur-
den, resistance and disease progression eventually occur. A major mechanism underlying
this resistance is increased levels of cellular DNA repair. Most cells have complex mecha-
nisms in place to repair DNA damage that occurs due to environmental exposures or normal
metabolic processes. These systems, initially overwhelmed when faced with chemother-
apy induced DNA damage, become more efficient under constant selective pressure and
as a result chemotherapies become less effective. Thus, inhibiting DNA repair pathways
using target specific small molecule inhibitors may overcome cellular resistance to DNA
damaging chemotherapies. Non-homologous end joining a major mechanism for the repair
of double-strand breaks (DSB) in DNA is regulated in part by the serine/threonine kinase,
DNA dependent protein kinase (DNA-PK). The DNA-PK holoenzyme acts as a scaffold pro-
tein tethering broken DNA ends and recruiting other repair molecules. It also has enzymatic
activity that may be involved in DNA damage signaling. Because of its’ central role in repair
of DSBs, DNA-PK has been the focus of a number of small molecule studies. In these stud-
ies specific DNA-PK inhibitors have shown efficacy in synergizing chemotherapies in vitro.
However, compounds currently known to specifically inhibit DNA-PK are limited by poor
pharmacokinetics: these compounds have poor solubility and have high metabolic labil-
ity in vivo leading to short serum half-lives. Future improvement in DNA-PK inhibition will
likely be achieved by designing new molecules based on the recently reported crystallo-
graphic structure of DNA-PK. Computer based drug design will not only assist in identifying
novel functional moieties to replace the metabolically labile morpholino group but will also
facilitate the design of molecules to target the DNA-PKcs/Ku80 interface or one of the
autophosphorylation sites.
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INTRODUCTION
Many first-line cancer therapies employ DNA damaging
chemotherapeutic agents alone or in combination with ioniz-
ing radiation (IR; Seymour et al., 2007; Cardoso et al., 2009; Tol
et al., 2009; Raftery and Goldberg, 2010). These therapies primar-
ily target genomic DNA resulting in the formation of highly toxic
double-strand DNA breaks (DSBs) leading to cell cycle arrest and
cell death. Problematic to cancer treatment, cells have multiple
mechanisms for repairing DSBs including homologous recombi-
nation (HR; Johnson and Jasin, 2001; Kao et al., 2005; Sung and
Klein, 2006) and non-homologous end joining (NHEJ; Burma
et al., 2006; Lieber et al., 2006; Bennardo et al., 2008; Lieber, 2008).
HR, an error free repair process, depends on the availability of a
homologous DNA template and, as such, functions primarily in
the G2/M phase of the cell cycle when sister chromatids are in
close proximity. NHEJ, although error prone compared to HR,
is thought to be the main pathway for the repair of DNA DSBs.
This pathway is able to function at all stages of the cell cycle and
does not require the presence of a homologous template. The risk
of mutation to an essential gene as a result of NHEJ is balanced
by the benefit of avoiding catastrophic cell division in the pres-
ence of DSBs. As such, it has been hypothesized that targeting the
molecular machinery driving the DNA damage response (DDR),
particularly NHEJ and DSB repair, with small molecule inhibitors,
will effectively enhance the efficacy of current cancer treatments
that generate DNA damage.
DNA DEPENDENT PROTEIN KINASE
One such target, DNA dependent protein kinase (DNA-PK), a
nuclear serine/threonine kinase, is a critical protein facilitating
NHEJ (Durocher and Jackson, 2001; Yang et al., 2003, 2009; Col-
lis et al., 2005; Dobbs et al., 2010; Neal and Meek, 2011; Neal
et al., 2011). The DNA-PK holoenzyme is composed a regulatory
heterodimer (Ku70 and Ku80 subunits) and a 460 kD catalytic
component, DNA-PKcs. Based on amino acid sequence homol-
ogy DNA-PK is a member of the phosphatidylinositol-3-kinase
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superfamily, however, since it possesses no apparent lipid kinase
activity it has been classified along with Ataxia Telangiectasia
Mutated (ATM), Ataxia Telangiectasia and Rad3 Related (ATR),
Mammalian Target of Rapamycin (m-Tor), and Suppressor of
Morphogenesis in Genitalia-1 (SMG-1) as part of the phosphatidyl
inositol 3-kinase-like (PIKK) protein kinase group (Durocher and
Jackson, 2001). Along with ATM and ATR, DNA-PK has a cen-
tral function in the DSB response and collectively these three
kinases are capable of phosphorylating upwards of 700 proteins
(in vitro; Callen et al., 2009). DNA-PK itself is a target of ATM
and ATR and is essential to NHEJ, V(D)J recombination and
class switch recombination (Ma et al., 2002; Callen et al., 2009;
Neal and Meek, 2011), all of which require the repair of DSBs.
In vitro DNA-PKcs is activated by free DNA ends and is capa-
ble of phosphorylating several protein substrates including the
Ku70/80 heterodimer, histone variant H2AX, replication asso-
ciated protein A (RPA), and autophosphorylation (Stiff et al.,
2004; Reitsema et al., 2005; Wang et al., 2005; Mukherjee et al.,
2006; Koike et al., 2008; An et al., 2010). Furthermore, DNA-PK
depended phosphorylation of S473 of AKT in response to plat-
inum based chemotherapy has been shown to inhibit apoptotic
response limiting drug efficacy (Stronack et al., 2011). There is also
in vitro evidence that DNA-PK interacts with or influences p53 and
p21 activities leading to cellular senescence and apoptosis (Azad
et al., 2011; Rudolf et al., 2011; Stronack et al., 2011; Wei et al.,
2012). Even so, only a few in vivo DNA-PK substrates are known,
these include DNA-PKcs autophosphorylation and histone vari-
ant H2AX. H2AX phosphorylation on S139 (γH2AX) has been
linked to Akt activity downstream of DNA-PK with S473 of Akt
being phosphorylated by DNA-PK. In response to this phosphory-
lation GSK3β, a negative regulator of DNA-PK, is phosphorylated
on Ser9 which prevents GSK3β from dephosphorylating γH2AX
(An et al., 2010). Despite the small number of substrates identi-
fied in vivo DNA-PK kinase activity is essential to efficient DSB
repair as only wild type and not kinase dead enzyme can rescue
IR sensitivity in DNA-PKcs defective V3 cells (Chen et al., 2005).
Furthermore, cells displaying resistance to DNA damaging agents
had increased levels of DNA-PKcs activity and cells deficient in
DNA-PKcs had enhanced sensitivity to DNA damaging agents
(Soubeyrand et al., 2003; Shinohara et al., 2005; Morris et al.,
2011). Also, although phosphorylation of DNA-PK and DNA-PK
kinase activity are not required for initial recruitment to DNA
damage sites they are required for efficient repair of DSBs (Davis
et al., 2010). It has been proposed that DNA-PK functions as a
scaffolding protein to align the broken DNA ends and assist in
the localization of repair factors. It may also play a regulatory
role by physically blocking unrepaired DNA ends preventing their
degradation, then, through autophosphorylation, releasing them
for repair once proper alignment has been achieved (Neal and
Meek, 2011; Neal et al., 2011).
Of note, a recent review by Kong et al. (2011) discusses
physiological functions of DNA-PK beyond its’ role in DNA repair.
These authors note that the abundant expression of the large
DNA-PK protein molecule in numerous cell types does not impart
improved DNA repair abilities, suggesting other important func-
tions for this molecule may exist. Evidence presented suggests
that DNA-PK has important roles in regulating gene response
to feeding/insulin stimulation. Furthermore, it is suggested that
DNA-PK has an active part in the regulation of homeostasis of cell
proliferation. Given that cancer cells generally have a high rate of
proliferation and have a high rate of metabolic activity these addi-
tional functions suggest further mechanisms by which DNA-PK
inhibition can target cancer cells.
MECHANISM
Regarding the role of DNA-PK in DNA repair a recent model of
NHEJ was proposed by Neal and Meek (2011) that suggests DSB
repair is initiated when the regulatory component of DNA-PK,
Ku70/Ku80, comes in contact with DNA ends at DSB sites. The
Ku heterodimer, which is able to bind to various double-stranded
end structures (blunt ends, 3′ or 5′ overhangs, covalently closed
hairpins) in a sequence independent manner, forms an asymmet-
ric ring that encircles double-stranded DNA ends. Subsequently,
DNA-PKcs is recruited and binds to the C-terminal portion of
Ku80 (Morris et al., 2011). DNA bound Ku then translocates
inwards away from the broken end significantly stimulating the
kinase activity of DNA-PKcs. It is proposed that homo-dimeric
interaction of DNA bound DNA-PK complexes brings corre-
sponding broken ends into close proximity and subsequently acts
as a scaffold for recruiting downstream repair proteins such as
XRCC4, DNA ligase IV, Artemis, XLF, and aprataxin. Activity of
this larger protein complex ultimately results in the repair of DSBs
(Kuo et al., 2006; Mansour et al., 2008). Molecular models of
DNA-PK associated DSB repair have been reviewed in detail by
Thompson (2012). The initial step of DSB repair occurs rapidly
with both ATM and DNA-PK being recruited to DNA damage
sites. DNA-PK is recruited within 60 s and recruitment peaks after
10 min. In contrast ATM recruitment peaks after 20 min. DNA-PK
rapidly dissociates after reaching peak levels and in contrast ATM
lingers for a prolonged period. Dissociation of DNA-PK, ATM,
and other DNA repair factors from DSB sites is associated with
the resolution of γH2AX foci suggesting successful DSB repair.
In contrast, DNA-PK showed persistent localization in NHEJ defi-
cient cells (Uematsu et al., 2007). These data suggest a model where
DNA-PK and ATM hold separate and distinct functions in DSB
repair with DNA-PK functioning as a scaffold and ATM acting as
a signaling kinase.
PHOSPHORYLATION
DNA dependent protein kinase is clearly important for efficient
repair of DSBs and to date as many as 40 potential phosphoryla-
tion sites have been identified on DNA-PK with the majority of
these being located in two major clusters: (1) the ABCDE clus-
ter containing S2612, S2624, T2609, T2620, T2638, T2647 and 2)
the PQR cluster containing sites S2023, S2029, S2041, S2053, and
S2056 (Morris et al., 2011; Neal and Meek, 2011; Neal et al., 2011).
Mechanistically, experimental evidence suggests that unphospho-
rylated DNA-PK blocks DNA ends inhibiting efficient ligation
and that autophosphorylation generates a large conformational
change opening the structure of DNA-PK (Davis et al., 2010; Mor-
ris et al., 2011) releasing it from aligned DNA ends. For example,
cells expressing mutations at S2056 or T2609 have tight binding
of DNA-PK to DNA DSBs and a slow off rate at sites of DNA
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damage (Davis et al., 2010). The structure of the DNA-PKcs mol-
ecule has three major domains facilitating this functionality: a
kinase domain, a large N-terminal domain that includes two long
arms into which DNA is proposed to thread and a DNA binding
pocket. The phosphorylations of amino acids from the respective
clusters, S2056 (PQR) and T2609 (ABCDE), are likely distinctly
regulated events as the physical locations of these residues are far
apart (Chen et al., 2005). Furthermore, phosphorylations of these
clusters may be functionally distinct in that ABCDE and PQR clus-
ters were shown to regulate DNA end processing and DNA repair
pathway choice in a reciprocal manner. For example, blocking at
the amino acid cluster ABCDE inhibited end processing and HR
while blocking at the PQR cluster enhanced these processes. Addi-
tionally, it was observed that S2056 phosphorylation increased
incrementally and reached maximum levels at 50 Gy of IR. This
was in contrast to T2609 whose phosphorylation reached max-
imum levels at 10 Gy. Based on the use of ATM and DNA-PK
knockout cell lines and DNA-PK and ATM specific siRNAs, it was
proposed that the S2056 phosphorylation is an autophosphoryla-
tion event that occurs in trans while the T2609 phosphorylation
is at least in part due to ATM activity (Collis et al., 2005). Fur-
ther examining the role of autophosphorylation, Neal and Meek
(Neal and Meek, 2011; Neal et al., 2011) noted that DNA-PK a
relatively abundant protein inhibits the process of HR in a titrat-
able manner. They also noted that this inhibition is absolutely
dependent on its’ enzymatic activity and is distinctly modulated
by phosphorylation. Through extensive examination of various
phosphorylation sites they observed that some sites impact NHEJ
negatively while promoting HR. They concluded that failed NHEJ
results in increased HR and conversely that in most cases profi-
cient NHEJ inhibits HR. In summary current data suggests that
DNA-PK has two important phosphorylation sites: (1) a cluster
containing S2056 that is primarily autophosphorylated and (2) a
cluster containing sites T2609 and T2647 that are at least in part
phosphorylated by ATM. Phosphorylation at these sites is critical
as its absence results in retention of DNA-PK foci at damage sites
for longer periods. All of these together illustrate the potential
for blocking DNA repair by inhibiting DNA-PK phosphorylation.
Thus there is vast potential for the use of DNA-PK inhibitors in
enhancing DNA damaging chemotherapies.
DNA-PK INHIBITORS
As such, to date the most successful approach to DNA-PK inhi-
bition has been with small molecules that target the ATP binding
site of the kinase domain (Allen et al., 2003). Various investigators
using compound libraries have identified a small group of mole-
cules that effectively inhibit DNA-PK kinase activity (Figure 1).
However, despite their specificity and potency these molecules
have been hampered by poor pharmacokinetic properties.
One of the first identified inhibitors, wortmannin (1), a fura-
nosteroid metabolite of the fungiPenicillium funiculosum,has been
used experimentally to inhibit DNA-PK. It is a non-competitive
general inhibitor of PI-3 kinases and has an IC50 in the nanomolar
range (5 nM for PI3K and equipotent for DNA-PK). Its’ mode of
action involves the irreversible alkylation of lysine 802, an amino
acid residing in the active site of DNA-PKcs that is critical for
the phosphate transfer reaction. Experimentally wortmannin has
FIGURE 1 | Small molecule inhibitors of DNA-PK: (A) wortmannin, (B)
LY294002 derivatives, and (C) other molecules with demonstrated
inhibitory activity.
proven to be an effective radiosensitizer with a dose reduction fac-
tor (DRF) for IR at 10% survival between 1.4 and 3. Despite its’
experimental efficacy: lack of specificity, poor solubility in aque-
ous solution, and in vivo toxicity limit clinical application of this
compound (Collis et al., 2005).
LY294002 (2), a morpholine derivative of the plant flavonoid
quercetin, is also a non-specific DNA-PK inhibitor used in many
studies (Vlahos et al., 1994; Sauveur-Michel et al., 2009). It is a
competitive inhibitor that binds reversibly to the kinase domain of
DNA-PK with an IC50 of 1.4µM producing a DRF at 10% survival
with IR of 1.5–1.8 (Collis et al., 2005). Rapid metabolic clearance
(1 h), in vivo toxicity, and lack of specificity make clinical evalua-
tion unfeasible in humans. However, LY294002 has proven to be
a productive lead compound and biochemical modifications have
produced a series of compounds with more favorable properties
(Fuhrman et al., 2008; Clapham et al., 2011). These modifications
using LY294002 as template have improved specificity with regards
to DNA-PK inhibition (Ihmaid et al., 2011).
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One such compound NU7026 (3) was over 50 fold more selec-
tive for DNA-PK than other PI-3Ks including ATM and ATR.
NU7026 had an IC50 of 0.23µM for DNA-PK, 13µM for PI3K,
and >100µM for ATM or ATR (Peddi et al., 2010). Further-
more, this drug potentiated the growth inhibition of a variety
of chemotherapeutic agents including: idarubicin, daunorubicin,
doxorubicin, etoposide, amsacrine, mitoxantrone but did not
potentiate camptothecin or cytosine arabinoside (Willmore et al.,
2004). Cell based assays showed a DRF for this drug with IR
at 10% survival of mouse embryonic fibroblasts of 1.5 (Nutley
et al., 2005). However, metabolic lability remains problematic as
monohydroxylation occurs on position 2 of the morpholino group
resulting in opening of the morpholino ring. Thus it is not likely
that sufficiently high concentrations of this drug can be obtained
in patients over the 4 h period required to synergize radiation and
or chemotherapy. Furthermore, poor solubility in saline solutions
limits the use of osmotic mini pumps. It has been suggested that
the 2-morpholin-4-yl substituent is required for inhibitory activ-
ity. As such attempts have been made to maintain this structure
while modifying other parts of the molecule to improve pharmaco-
kinetics. Problematically the core ring structure is not conducive to
chemical modifications. As such, Hollick et al. proposed modifica-
tion of pyran-4-ones and thiopyran-4-ones and obtained suitably
potent and selective DNA-PK inhibitors. Although this approach
obtained novel compounds screening continues to identify com-
pounds with improved biological and pharmaceutical properties
(Hollick et al., 2003).
NU7441 (4) another drug based on the LY294002 backbone
with improved potency showed similar promise to NU7026. In
cell lines it showed strong inhibition of DNA-PK with an IC50 of
0.3µM for DNA-PK and 7µM for PI3K. In the presence of this
compound doxorubicin and IR induced DSBs persisted for pro-
longed periods and HR activity increased modestly (Rad51 foci;
Tavecchio et al., 2012). Zhao and Curtin (Zhao et al., 2006) noted
that NU7441 increased the cytotoxicity of IR and etoposide in
SW620, LoVo, and V3-YAC colon cancer cells but not in V3 cells
indicating that potentiation of DNA damage and cell death was
largely due to DNA-PK inhibition. Furthermore, NU7441 sub-
stantially delayed the repair of IR and etoposide induced DSBs
and appreciably increased G2/M accumulation associated with
IR, etoposide and doxorubicin in SW620, and LoVo colon cancer
cells. In xenograft colon cancer models NU7441 concentrations
in the tumor necessary for chemopotentiation in vitro were main-
tained for at least 4 h at non-toxic doses, a significant improvement
over NU7026. Additionally, etoposide induced tumor growth delay
was increased two-fold without enhancing toxicity. Thus experi-
ments with NU7441 have shown that pharmacokinetics of these
inhibitors can be improved but their marginal effects on radiation
and chemotherapy have halted further development.
Other compounds based on the LY294002 structure have been
tested including IC86621 (5), IC87102 (6), and IC87361 (7). In
cell culture these recapitulate the phenotype of DNA-PK defective
cell lines including those from SCID mice and directly inhibit the
repair of DNA DSBs and enhance the cytotoxicity of physical and
chemical agents that induce DSB formation. As with other com-
pounds tested IC86621 showed increased sensitization to IR and
decreased repair of spontaneous and IR induced DSBs. Since, these
compounds are non-toxic there main therapeutic potential is to
enhance the effects of DNA damaging therapies on cancer cells
(Kashishian et al., 2003). DNA-PKcs was strongly inhibited and
even at concentrations of 100µM, IC86621 had no activity against
the closely related protein kinases ATM, ATR, or FRAP. Addition-
ally, IC87361 showed significant radiosensitization at 6 Gy and
significant growth delay in xenograft models. At 10µM concen-
trations this drug had no intrinsic growth inhibitory properties
but significantly potentiated the effect of radiation in ovarian can-
cer cells. It was observed that at least 4 h exposure to a 10µM
concentration of this drug was required for radiosensitization and
that 24 h of exposure further improved this effect. This time of
drug exposure is likely to be important for positive therapeutic
effects and illustrates that pharmacokinetic properties such as:
rapid clearance from circulation and low bioavailability (Shino-
hara et al., 2005) are the major barriers to the clinical use of these
compounds.
Other compounds based on different chemical structures and
found to have inhibitory activity against DNA-PK include OK-
1035 (8) and SU11752 (9). OK-1035 with an IC50 for DNA-PK of
100µM is unlikely to be a useful drug in vivo (Take et al., 1996).
Similarly, SU11752 was shown to lack the required potency for
in vivo studies.
The phenolic aldehyde vanillin (10), derived from some species
of vanilla pods, has also been shown to inhibit DNA-PK in cell
free extracts. This inhibition was shown to be specific to NHEJ
and selective for DNA-PK over ATM and ATR with a DRF of 1.3
at 10% survival following IR of human ovarian carcinoma cells
(Durant and Karran, 2003).
Recently the anticancer agent NK314 (11), possessing activ-
ity against topoisomerase II alpha (TIIα), was shown to induce
the degradation of DNA-PKcs resulting in impaired DNA DSB
repair. In other words NK314 appears to be an inhibitor with dual
specificities for TIIα and DNA-PKcs with potential activity against
adult T-cell leukemia-lymphoma (ATL; Hisatomi et al., 2011).
Although the mechanism by which this drug inhibits DNA-PK
remains unclear it illustrates the potential for combining DNA-
PK activity with chemotherapeutics. The combination is in this
case all the more effective because the two activities are deliv-
ered as a single reagent. This drug is currently in clinical trials for
the treatment of ATL illustrating the potential for using DNA-PK
inhibitors in the clinic.
Recent studies in our laboratory have explored the efficacy
of acridone based compounds as DNA-PK inhibitors (David-
son et al., 2012a,b). These studies sought to measure the degree
of synergy induced by the specific small molecule inhibitor of
DNA-PK, IC486241 (ICC) (12), with irinotecan (SN38) or oxali-
platin. Significant reductions in the IC50 values of SN38 were
observed at 5 and 10µM of DNA-PK inhibitors. Moreover, at
1–2µM (attainable concentrations with ICC in mice), these DNA-
PKcs inhibitors demonstrated synergistic reductions in the IC50 of
SN38. Flow cytometric data indicated that SN38 and SN38 in com-
bination with DNA-PKcs inhibitors showed dramatic G2/M arrest
at 24 h. Furthermore, reduced phosphorylation of DNA-PKcs and
increased DNA damage were observed at this time point with
SN38 in combination with DNA-PKcs inhibitors as compared to
cells treated with SN38 alone. SN38 alone and in the presence of
ICC increased nuclear Rad51 protein levels. Furthermore, inhi-
bition of DNA-PKcs increased HRR suggesting that NHEJ is a
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negative regulator of HRR. This observation was corroborated by
Neal et al. (2011), who showed that DNA-PK enzymatic activ-
ity could inhibit HRR in a titratable fashion. In addition these
authors also showed that some phosphorylations of DNA-PK had
the opposite effect, that is to say, inhibition of NHEJ and promo-
tion of HRR. Of interest, Amrein et al. (2011) observed a similar
relationship between the HRR and NHEJ pathways in chronic lym-
phocytic leukemia (CLL) lymphocytes treated with chlorambucil
(CLB). Imatinib and Nilotinib, two potent inhibitors of the non-
receptor tyrosine kinase c-abl, caused a reduction in HRR and
a corresponding increase in DNA-PK (NHEJ) activity. Together
these observations suggest that DNA-PK has a significant func-
tion in choosing the pathway of DNA repair. A similar series
of experiments showed the degree to which ICC synergizes the
cytotoxicity of DNA damaging agents in three genetically diverse
breast cancer cell lines. In this study, improved cytotoxicity and
significant synergy were observed with both anticancer agents in
the presence of non-toxic concentrations of ICC. Moreover, ICC
decreased doxorubicin-induced DNA-PKcs autophosphorylation
on Ser2056 and increased doxorubicin-induced DNA fragmen-
tation. Thus, the novel DNA-PKcs inhibitor, ICC, synergistically
sensitized 3 breast cancer cell lines to doxorubicin and cisplatin.
Enhanced efficacy of doxorubicin was achieved by inhibiting NHEJ
resulting in increased accumulation of DNA damage. Pharmaco-
kinetic studies of these compounds in mice showed maximum
serum concentrations of 4.6µM 1 min post intravenous injec-
tion and terminal serum half-lives of 23.8 min (personal com-
munication, Luipold pharmaceuticals). Thus although this drug
shows promising synergy with chemotherapeutics in cell culture,
future use will depend on developing compounds with improved
solubility and serum half-life.
NUCLEOTIDE AND ANTIBODY INHIBITORS
Although the majority of studies have focused on the use of small
organic compounds to inhibit DNA-PK, a few have focused on
nucleotide and antibody based inhibitors and shown that these
may also have clinical efficacy in the inhibition of DNA-PK. In
fact due to the biological nature of these molecules they may
overcome the two primary obstacles faced by small organic com-
pounds known to inhibit DNA-PK, namely: poor solubility’s and
short serum half-lives. GRN163L (Imetelstat; GRN), a 13-mer
oligonucleotide developed as a direct inhibitor of the telomerase
active site illustrates how nucleotides can influence DNA-PK func-
tion. In a recent study in CLL lymphocytes this molecule was
shown to inhibit DNA-PK phosphorylation and increase H2AX
phosphorylation in response to treatment with the nucleotide ana-
log fludarabine (flu; Shawi et al., 2011). The authors observed that
activity was correlated with low expression levels of the DNA-PK
subunit Ku80 and that GRN inhibited DNA-PK phosphoryla-
tion at a level equivalent to NU7026. Together these observations
indicate that GRN in addition to inhibiting telomerase activity
enhances chemotherapy by inhibiting DNA-PK activity and repair
of DNA damage. It would be of significant interest to know if GRN
synergizes the killing of other cancer types in the presence of a
variety of DNA damaging therapies.
In addition to oligonucleotides, antibody based inhibitors
may also have a role to play in DNA-PK inhibition. Antibodies,
although effective in the inhibition of cell surface targets (Scott,
2012) are typically ineffective against intracellular targets because
of their inability to penetrate the plasma membrane (Cardinale
and Biocca, 2008). However, recent work in which the DNA-PK
specific single-chain antibody variable region fragment ScFv 18-2
was linked to folate via a scissile disulfide linker showed efficacy in
delivering the antibody fragment to cell nuclei via folate mediated
endocytosis. This product resulted in decreased DNA-PK phos-
phorylation, increased H2AX phosphorylation, and radiosensi-
tization (Xiong et al., 2011). This work is of interested for a
number of reasons. Firstly, it illustrates the potential of antibody
based therapies that target intracellular molecules such as DNA-
PK and secondly it illustrates the efficacy of combi-molecules
composed of a cell surface receptor substrate and a chemother-
apeutic agent. The receptor substrate as in this case can facilitate
transit of the plasma and nuclear membranes but may also be
used to target drugs to cancers over-expressing specific surface
receptors.
In conclusion DNA-PK inhibition using small molecule
inhibitors holds promise for improving cancer therapy. However,
molecules currently known to specifically inhibit DNA-PK are
limited by poor pharmacokinetics: metabolic lability leads to a
short serum half-life. Future improvement in DNA-PK inhibition
will likely be achieved by designing new molecules based on the
recently reported crystallographic structure of DNA-PK (Sibanda
et al., 2010; Ihmaid et al., 2012). Computer based drug design will
not only assist in identifying novel functional moieties to replace
the metabolically labile morpholino group but will also facilitate
the design of molecules to target the DNA-PKcs/Ku80 interface or
one of the autophosphorylation sites. Of significant interest novel
approaches using DNA-PK specific antibodies or oligonucleotides
may also be of great value as they may overcome the fundamen-
tal weaknesses of currently available small molecule inhibitors of
DNA-PK, namely: poor solubility and short serum half-life. To
date the latter have only been tested against DNA-PK in vitro,
future work will demonstrate if these approaches have significant
in vivo efficacy.
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